Kenro Capital.
India's first dedicated growth-secondaries firm: built by the man who ran Peak XV's internal liquidity desk. Over $120M deployed in year one: K12 Techno, a Pine Labs pre-IPO block that listed within months, and GIVA.
GW GP Score
Kenro is a pure bet on the structural fact this platform documents everywhere else: Indian VC's 2015-2020 vintages need liquidity, 85% of secondaries clear at par, and the IPO queue gives 2-3 year exit visibility. Piyush Gupta ran exactly this trade inside Peak XV for seven years; now he runs it for his own book, buying $20-30M minority stakes in near-profitable companies with a listing path. Pine Labs validated the model fast: bought pre-IPO, listed November 2025. Fund size undisclosed is the honesty gap.
Conditional hold: enough signal to track closely, not enough to underwrite without the next proof point.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Fund size / LP disclosure: none as of Jul 2026.
Post-listing behaviour in Pine Labs (hold vs sell): first realisation datapoint.
A shut IPO window converts the whole book into duration risk at undisclosed leverage/economics.
Computed from current dossier sources; analyst override pending.
The right strategy at the right moment, executed fast by the person who invented the trade at Peak XV: held to G3 by structural opacity and two-person key-man risk.
Three positions; Pine Labs already listed, GIVA marked up 22%
No distributions yet; Pine Labs listing is mark validation, not cash
Purpose-built for the exact liquidity gap the Indian cycle has now
>$120M year one: real; but against an undisclosed base
Two deeply experienced founders; no bench
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Current evidence supports the score, but not enough to move it without a fresh exit, fund close or team signal.
Post-listing behaviour in Pine Labs (hold vs sell): first realisation datapoint.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
Fund size / LP disclosure: none as of Jul 2026.
The strategy self-evidently works in this cycle; the diligence problem is the vehicle, not the thesis. Demand the fund size and concentration limits nobody else has published.
A shut IPO window converts the whole book into duration risk at undisclosed leverage/economics.
Fund size / LP disclosure: none as of Jul 2026.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 1 pressure catalyst(s); top driver: India PE-VC value down 5% YoY in H1 CY2026.
The broad private-capital backdrop is selective rather than euphoric; fundraising and mark support now need firm-specific proof.
Score pressureRaises the bar for weak-DPI managers and stale flagship vehicles; rewards funds with fresh closes or visible exits.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
The funds
Undisclosed · >$120M deployed in year one across 1 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| Kenro Capital Fund (Singapore) + India Secondary Fund | 2024Recovery / IPO window | Undisclosed | Growth secondaries | Two-vehicle structure per PitchBook; deployment proxy >$120M year one |
Closest booksCreaegis (1 shared) · Premji Invest (1 shared) · India Quotient (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Vehicle cadence is neither freshly restocked nor visibly stale.
Next liquidityGIVA
1 visible exit events since Jul 2024.
Vehicle cadence is neither freshly restocked nor visibly stale.
3 up / 0 flat / 0 down tracked signals.
No senior departure flagged in key people.
3 up / 0 flat / 0 down
1 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Exit-led repricing; entry discipline decisive
Series C extension at ~₹4,900 Cr (+22%); alongside Premji Invest, Titan Capital
At least one cited source is dated 2026.
1 visible events tracked.
3 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 2 · -1
Peer median 2 · -1
Peer median 74 · -17
Peer median 62 · +39
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Exit data, Portfolio data, Team data, Performance proxy evidence remains low-confidence despite a scored dossier.
Current · At least one cited source is dated 2026.
Upgrade the weak fields with dated facts before the next score action: Exit data, Portfolio data, Team data, Performance proxy.
Prioritise filings and firm disclosures; mark estimates as GW E until then.
Post-listing behaviour in Pine Labs (hold vs sell): first realisation datapoint.
GIVA: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Exit data, Portfolio data, Team data, Performance proxy.
5 total sources · 20% primary
At least one cited source is dated 2026.
Entrackr: GIVA Series C extension (Feb 2026)
Upgrade Exit data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
Three disclosed positions in year one: deliberately concentrated secondaries.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| K12 Techno (Orchids Schools) | Consumer & Commerce | 2024 | Secondary (~$40M) | Private | ▲ | Maiden deal Dec 2024: stakes from Peak XV & Sofina + ESOP liquidity + small primary |
| Pine Labs | Fintech | 2025 | Pre-IPO secondary ($30-40M, R) | Public | ▲ | Listed Nov 2025 at ~$2.86bn: the model's fast validation |
| GIVA | Consumer & Commerce | 2026 | Secondary + ₹13.75 Cr primary | Soonicorn | ▲ | Series C extension at ~₹4,900 Cr (+22%); alongside Premji Invest, Titan Capital |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
The buying pattern is exactly the pitch: profitable-adjacent companies (schools, payments, jewellery) with 2-3 year listing paths, purchased from funds that need DPI. Kenro sits on the OTHER side of the liquidity trade every other dossier on this platform describes.
At ~$545M valuation
$30-40M reported range
Realisation · are LPs getting paid?
Too young for realised distributions, but Pine Labs listing inside a year of purchase is precisely the underwriting case. The book is a claim on the 2026-27 IPO window at secondary-entry prices.
Position listed within months of purchase: mark-to-market validation; sale/hold behaviour post-listing undisclosed.
Firm-stated (DealStreetAsia bio): the best available proxy given undisclosed fund size
Bought pre-IPO, listed Nov 2025
Size, LPs, economics all undisclosed
No fund size, no LPs named, no returns: judge it on deal flow and counterparties (Peak XV and Sofina sold to it; Premji co-invested beside it). GW read: the strategy is the right trade at the right time; the vehicle is a black box. E.
What they're doing
Growth secondaries only: buy minority stakes from liquidity-seeking funds at/near par, in companies with revenue scale and 2-3 year IPO paths.
$20-30M cheques, larger via co-invest; India + SEA with India majority.
Company-first underwriting: sector, management execution, operating history across cycles.
Buy FROM the big franchises, cooperatively: K12 came from Peak XV itself.
What can break
A shut IPO window converts the whole book into duration risk at undisclosed leverage/economics.
Two-partner shop with no disclosed bench or fund size: institutional counterparties are extending trust on biography.
Competition arriving fast: Oister ACE series, TR Capital, Kotak's ~$1.6bn strategy: par pricing may become premium pricing.
Fund size / LP disclosure: none as of Jul 2026.
Post-listing behaviour in Pine Labs (hold vs sell): first realisation datapoint.
Deployment pace vs the arriving secondaries competition (Oister ACE III, Kotak).
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
The strategy self-evidently works in this cycle; the diligence problem is the vehicle, not the thesis. Demand the fund size and concentration limits nobody else has published.
Kenro is your DPI counterparty, not your competitor: it exists to buy your 2015-2019 positions at par. Its bid is the honest floor for your marks.
Where Kenro buys is a forward IPO-supply signal: K12 (education services), Pine Labs (payments), GIVA (jewellery D2C) all map to 2026-27 listing lanes.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.